These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2568898)

  • 1. A critical review of continuous infusion H2 receptor therapy.
    Rovers JP; Souney PF
    Crit Care Med; 1989 Aug; 17(8):814-21. PubMed ID: 2568898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A controlled comparison of continuous ranitidine and intermittent famotidine infusions on gastric pH.
    Bachmann K; Sullivan TJ; Jauregui L
    J Clin Pharmacol; 1993 Dec; 33(12):1219-24. PubMed ID: 7907348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of famotidine with cimetidine and ranitidine.
    Berardi RR; Tankanow RM; Nostrant TT
    Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics and pharmacokinetics of parenteral histamine (H2)-receptor antagonists.
    Ostro MJ
    Am J Med; 1987 Dec; 83(6A):15-22. PubMed ID: 2892405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of gastric secretion in man with a new H2-receptor antagonist, ranitidine.
    Kett K; Aadland E; Berstad A
    Scand J Gastroenterol; 1980; 15(2):249-51. PubMed ID: 6104355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overnight comparable anacidity by standard large and half-single bedtime doses of H2 antagonists in duodenal ulcer patients: a clinical pharmacological study.
    Savarino V; Mela GS; Scalabrini P; Sumberaz A; Fera G; Zentilin P; Celle G
    Am J Gastroenterol; 1988 Sep; 83(9):917-22. PubMed ID: 2901220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children.
    Madani S; Kauffman R; Simpson P; Lehr VT; Lai ML; Sarniak A; Tolia V
    J Clin Pharmacol; 2014 Feb; 54(2):201-5. PubMed ID: 24258773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving pH control in the critically ill patient: the role of continuous infusion of H2-receptor antagonists.
    Moore JG
    DICP; 1990 Nov; 24(11 Suppl):S28-30. PubMed ID: 1980180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative studies on hemodynamic effects of intravenous cimetidine, ranitidine and famotidine in intensive care unit patients].
    Omote K; Namiki A; Sumita S; Takahashi T; Ujike Y; Hagiwara T
    Masui; 1987 Jun; 36(6):940-7. PubMed ID: 2888909
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative efficacy of parenteral histamine (H2)-antagonists in acid suppression for the prevention of stress ulceration.
    Critchlow JF
    Am J Med; 1987 Dec; 83(6A):23-8. PubMed ID: 2892406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bolus or intravenous infusion of ranitidine: effects on gastric pH and acid secretion. A comparison of relative efficacy and cost.
    Ballesteros MA; Hogan DL; Koss MA; Isenberg JI
    Ann Intern Med; 1990 Mar; 112(5):334-9. PubMed ID: 2306061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of bolus famotidine versus infused cimetidine, ranitidine, and famotidine.
    Amsden GW; Goss TF; Harrison NJ; D'Andrea DT; Schentag JJ
    J Clin Pharmacol; 1994 Dec; 34(12):1191-8. PubMed ID: 7738215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?
    Fiorucci S; Clausi GG; Farinelli M; Santucci L; Farroni F; Pelli MA; Morelli A
    Am J Gastroenterol; 1988 Dec; 83(12):1371-5. PubMed ID: 2904218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of continuous infusion of histamine2-receptor antagonists in critically ill patients.
    Siepler JK; Trudeau W; Petty DE
    DICP; 1989 Oct; 23(10 Suppl):S40-3. PubMed ID: 2573209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerations for selection of parenteral histamine (H2)-receptor antagonists.
    Wolfe MM
    Am J Med; 1987 Dec; 83(6A):82-8. PubMed ID: 2892411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dosage alternative for H2-receptor antagonists--constant infusion.
    Siepler JK
    Clin Ther; 1986; 8 Suppl A():24-33. PubMed ID: 2878728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Famotidine in the therapy of gastric hypersecretory states.
    Vinayek R; Howard JM; Maton PN; Wank SA; Slaff JI; Gardner JD; Jensen RT
    Am J Med; 1986 Oct; 81(4B):49-59. PubMed ID: 2877575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine.
    Oh T; Franko TG
    Am J Hosp Pharm; 1990 Jul; 47(7):1547-51. PubMed ID: 2114789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stress ulceration in the intensive care unit: use of H2-receptor antagonists.
    Moore JG
    Aliment Pharmacol Ther; 1991; 5 Suppl 1():111-9. PubMed ID: 1679669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.